In a report released today, Drew Ranieri from Morgan Stanley maintained a Sell rating on Avanos Medical (AVNS – Research Report), with a price target of $26.00. The company’s shares opened today at $23.53.
Ranieri covers the Healthcare sector, focusing on stocks such as Baxter International, Integra Lifesciences, and Avanos Medical. According to TipRanks, Ranieri has an average return of -1.9% and a 45.98% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Avanos Medical with a $25.50 average price target.
See today’s best-performing stocks on TipRanks >>
AVNS market cap is currently $1.14B and has a P/E ratio of 26.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avanos Medical, Inc. is a medical technology company, which focuses on delivering clinically medical device solutions to improve patients’ quality of life. Its portfolio of innovative product offerings focused on respiratory and digestive health, along with surgical and interventional pain management to improve patient outcomes and reduce the cost of care. Its brands include ON-Q, Coolife, Microcuff, MIC-Key, Quilbloc and Home pump. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.
Read More on AVNS:
